TVRD
Tvardi Therapeutics, Inc.
$4.12
0.1
(2.49%)
| Exchange: | |
| Market Cap: | 38.651M |
| Shares Outstanding: | 1.317M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Imran Alibhai | |||||
| Full Time Employees: | 17 | |||||
| Address: |
|
|||||
| Website: | https://tvarditherapeutics.com BioSpace +4 |
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
